US Patent

US9339497 — Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Method of Use · Assigned to Merrimack Pharmaceuticals Inc · Expires 2033-06-12 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating pancreatic cancer using liposomal irinotecan alone or in combination with other therapeutic agents.

USPTO Abstract

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Drugs covered by this patent

Camptosar (Irinotecan Hydrochloride) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1848`	—	Camptosar

Patent Metadata

Patent number: US9339497
Jurisdiction: US
Classification: Method of Use
Expires: 2033-06-12
Drug substance claim: No
Drug product claim: No
Assignee: Merrimack Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.